Heparanase activity and bone loss in postmenopausal breast cancer patients [3]

Journal of Clinical Oncology

Volumn 23, Issue 34, 2005, Pages 8916-8917

  Altundag, Kadri ^a   Altundag, Ozden ^a   Baptista, Mauricio Z ^b   Akyurek, Serap ^c  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Hospital Maternidade de Campinas   (Brazil)

^c ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; EXEMESTANE; HEPARAN SULFATE; HEPARANASE; HOMOCYSTEINE; ANDROSTANE DERIVATIVE; AROMATASE INHIBITOR; BETA GLUCURONIDASE;

BONE DENSITY; BONE MARROW; BONE REMODELING; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER RISK; CLINICAL FEATURE; CLINICAL TRIAL; ENZYME ACTIVITY; FEMUR NECK; HUMAN; LETTER; LYMPH NODE METASTASIS; MENOPAUSAL SYNDROME; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; BREAST TUMOR; DRUG EFFECT; ENZYMOLOGY; FEMALE; METABOLISM; NOTE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS;

ANDROSTADIENES; AROMATASE INHIBITORS; BONE DENSITY; BONE RESORPTION; BREAST NEOPLASMS; FEMALE; GLUCURONIDASE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE;

EID: 33644836409     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.0121     Document Type: Letter

References (2)

1. Lønning PE, Geisler J, Krag LE, et al: Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23:5126-5137, 2005
2. Kelly T, Silva LJ, Huang Y, et al: Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Res 65:5778-5784, 2005